Maximum quantity allowed is 999
Please select the quantity
CAS RN: 16676-29-2 | Product Number: N1176
Naltrexone Hydrochloride
Purity: >98.0%(GC)(HPLC)
Synonyms:
- Trexan
Product Documents:
Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time | Shipping Information |
---|---|---|---|---|---|
250MG |
$180.00
|
1 | 5 | Contact Us | |
1G |
$541.00
|
1 | 10 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
Product Number | N1176 |
Purity / Analysis Method | >98.0%(GC)(HPLC) |
Molecular Formula / Molecular Weight | C__2__0H__2__3NO__4·HCl = 377.87 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Store Under Inert Gas | Store under inert gas |
Condition to Avoid | Hygroscopic,Heat Sensitive |
Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image), 250MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 16676-29-2 |
Reaxys Registry Number | 3580333 |
PubChem Substance ID | 468592499 |
MDL Number | MFCD00069324 |
Specifications
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 % |
Water | max. 11.0 % |
Properties (reference)
Melting Point | 178 °C |
Solubility in water | Soluble |
GHS
Pictogram | |
Signal Word | Warning |
Hazard Statements | H302 : Harmful if swallowed. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
RTECS# | QD2160000 |
Transport Information:
H.S.code* | 2939.19-000 |
Application
Naltrexone Hydrochloride: A Long Acting Competitive Peripheral μ-Opioid Antagonist
Naltrexone hydrochloride, a long acting competitive peripheral μ-opioid antagonist, is a synthetic congener of opioid analgesics with little or no μ-opioid agonist properties.1) It is used for the treatment of opioid dependence and opioid-induced constipation, and is also used for alcohol dependence in US and EU.2,3) Recently, μ-opioid receptor is a potential target for cancer therapy because of its plausible role in tumor progression. Therefore, the μ-opioid antagonist naltrexone has received attention as a new anticancer agent with few side-effects (low-dose naltrexone, LDN).4,5) (The product is for research purpose only.)
References
- 1) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog
- 2) Alteration of ethanol self-administration by naltrexone
- 3) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence (a review)
- 4) The opioid growth factor-opioid growth factor receptor axis: Homeostatic regulator of cell proliferation and its implications for health and disease (a review)
- 5) Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.